Improve Research Reproducibility A Bio-protocol resource
CN


Rolf A. Brekken
  • Department of Surgery, Hamon Center for Therapeutic Oncology Research, USA
Research fields
  • Cancer biology
Personal information

Education

Ph.D., Southwestern Graduate School of Biomedical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas, 1999

Current position

Associate Professor, Division of surgical Oncology, Departments of Surgery & Pharmacology

Publications

Original Papers: 108 (105 published or in press, 3 submitted for publication)
H index = 38, December 2013
First or corresponding author publications

  1. Ostapoff, K. T., Cenik, B. K., Wang, M., Ye, R., Xu, X., Nugent, D., Hagopian, M. M., Topalovski, M., Rivera, L. B., Carroll, K. D. and Brekken, R. A. (2014). Neutralizing Murine TGFbetaR2 Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer Metastasis. Cancer Res 74(18): 4996-5007.
  2. Aguilera, K. Y., Rivera, L. B., Hur, H., Carbon, J. G., Toombs, J. E., Goldstein, C. D., Dellinger, M. T., Castrillon, D. H. and Brekken, R. A. (2014). Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 74(4): 1032-1044.
  3. Dellinger, M. T., Meadows, S. M., Wynne, K., Cleaver, O. and Brekken, R. A. (2013). Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature. PLoS One 8(9): e74686.
  4. Ostapoff, K. T., Awasthi, N., Cenik, B. K., Hinz, S., Dredge, K., Schwarz, R. E. and Brekken, R. A. (2013). PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther 12(7): 1190-1201.
  5. Kutluk Cenik, B., Ostapoff, K. T., Gerber, D. E. and Brekken, R. A. (2013). BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther 12(6): 992-1001.
  6. Kirane, A., Toombs, J. E., Ostapoff, K., Carbon, J. G., Zaknoen, S., Braunfeld, J., Schwarz, R. E., Burrows, F. J. and Brekken, R. A. (2012). Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 18(18): 5031-5042.
  7. Kirane, A., Toombs, J. E., Larsen, J. E., Ostapoff, K. T., Meshaw, K. R., Zaknoen, S., Brekken, R. A.* and Burrows, F. J.* (2012). Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 33(9): 1639-1646. (*Corresponding authors)
  8. Arnold, S. A., Rivera, L. B., Carbon, J. G., Toombs, J. E., Chang, C. L., Bradshaw, A. D. and Brekken, R. A. (2012). Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. PLoS One 7(2): e31384.
  9. Dellinger, M. T. and Brekken, R. A. (2011). Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. PloS One 6(12): e28947.
  10. Rivera, L. B. and Brekken, R. A. (2011). SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-beta1 activity. J Cell Biol 193(7): 1305-1319.
  11. Lynn, K. D., Udugamasooriya, D. G., Roland, C. L., Castrillon, D. H., Kodadek, T. J. and Brekken, R. A. (2010). GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 10: 397.
  12. Sullivan, L. A., Carbon, J. G., Roland, C. L., Toombs, J. E., Nyquist-Andersen, M., Kavlie, A., Schlunegger, K., Richardson, J. A. and Brekken, R. A. (2010). r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS One 5(8): e12031.
  13. Dineen, S. P., Roland, C. L., Greer, R., Carbon, J. G., Toombs, J. E., Gupta, P., Bardeesy, N., Sun, H., Williams, N., Minna, J. D. and Brekken, R. A. (2010). Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70(7): 2852-2861.
  14. Schluterman, M. K., Chapman, S. L., Korpanty, G., Ozumi, K., Fukai, T., Yanagisawa, H. and Brekken, R. A. (2010). Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech 3(5-6): 333-342.
  15. Arnold, S. A., Rivera, L. B., Miller, A. F., Carbon, J. G., Dineen, S. P., Xie, Y., Castrillon, D. H., Sage, E. H., Puolakkainen, P., Bradshaw, A. D. and Brekken, R. A. (2010). Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 3(1-2): 57-72.
  16. Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G. and Brekken, R. A. (2009). Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 4(11): e7669.
  17. Roland, C. L.*, Dineen, S. P.*, Lynn, K. D.*, Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S. and Brekken, R. A. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8(7): 1761-1771. (*Equal contribution)
  18. Dineen, S. P., Sullivan, L. A., Beck, A. W., Miller, A. F., Carbon, J. G., Mamluk, R., Wong, H. and Brekken, R. A. (2008). The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8: 352.
  19. Bull Phelps, S. L., Carbon, J., Miller, A., Castro-Rivera, E., Arnold, S., Brekken, R. A. and Lea, J. S. (2009). Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol 200(2): 180 e181-187. (*Co-corresponding authors)
  20. Arnold, S., Mira, E., Muneer, S., Korpanty, G., Beck, A. W., Holloway, S. E., Manes, S. and Brekken, R. A. (2008). Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 233(7): 860-873.
    *Best Basic Science Paper in 2008, SEBM
  21. Dineen, S. P., Lynn, K. D., Holloway, S. E., Miller, A. F., Sullivan, J. P., Shames, D. S., Beck, A. W., Barnett, C. C., Fleming, J. B. and Brekken, R. A. (2008). Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68(11): 4340-4346.
  22. Korpanty, G., Carbon, J. G., Grayburn, P. A., Fleming, J. B. and Brekken, R. A. (2007). Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13(1): 323-330.
  23. Holloway, S. E., Beck, A. W., Shivakumar, L., Shih, J., Fleming, J. B. and Brekken, R. A. (2006). Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surg Oncol 13(8): 1145-1155.
  24. Beck, A. W., Luster, T. A., Miller, A. F., Holloway, S. E., Conner, C. R., Barnett, C. C., Thorpe, P. E., Fleming, J. B. and Brekken, R. A. (2006). Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 118(10): 2639-2643.
  25. Korpanty, G., Grayburn, P. A., Shohet, R. V. and Brekken, R. A. (2005). Targeting vascular endothelium with avidin microbubbles. Ultrasound Med Biol 31(9): 1279-1283.
  26. Fleming, J. B., Shen, G. L., Holloway, S. E., Davis, M. and Brekken, R. A. (2005). Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 3(7): 413-423.
  27. Holloway, S. E., Beck, A. W., Girard, L., Jaber, M. R., Barnett, C. C., Jr., Brekken, R. A. and Fleming, J. B. (2005). Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 200(3): 371-377.
  28. Puolakkainen, P. A.*, Brekken, R. A.*#, Muneer, S. and Sage, E. H. (2004). Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2(4): 215-224. (*Equal contribution; #Corresponding author)
  29. Sweetwyne, M. T.*, Brekken, R. A.*, Workman, G., Bradshaw, A. D., Carbon, J., Siadak, A. W., Murri, C. and Sage, E. H. (2004). Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 52(6): 723-733. (*Equal contribution)
  30. Brekken, R. A., Sullivan, M. M., Workman, G., Bradshaw, A. D., Carbon, J., Siadak, A., Murri, C., Framson, P. E. and Sage, E. H. (2004). Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J Histochem Cytochem 52(6): 735-748.
  31. Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R. and Sage, E. H. (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111(4): 487-495.
  32. Brekken, R. A., Overholser, J. P., Stastny, V. A., Waltenberger, J., Minna, J. D. and Thorpe, P. E. (2000). Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60(18): 5117-5124.
  33. Brekken, R. A., Huang, X., King, S. W. and Thorpe, P. E. (1998). Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58(9): 1952-1959.

Contributing author publications

  1. Yang, L., Kwon, J., Popov, Y., Gajdos, G. B., Ordog, T., Brekken, R. A., Mukhopadhyay, D., Schuppan, D., Bi, Y., Simonetto, D. and Shah, V. H. (2014). Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 146(5): 1339-1350 e1331.
  2. D'Amico, G., Korhonen, E. A., Anisimov, A., Zarkada, G., Holopainen, T., Hagerling, R., Kiefer, F., Eklund, L., Sormunen, R., Elamaa, H., Brekken, R. A., Adams, R. H., Koh, G. Y., Saharinen, P. and Alitalo, K. (2014). Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J Clin Invest 124(2): 824-834.
  3. Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., McDonald, J. G., Yuhanna, I. S., Thompson, B., Girard, L., Mineo, C., Brekken, R. A., Umetani, M., Euhus, D. M., Xie, Y. and Shaul, P. W. (2013). 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 5(3): 637-645.
  4. Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Eskiocak, B., Chung, H., McMillan, E., Wu, S., De Brabander, J., Komurov, K., Toombs, J. E., Wei, S., Peyton, M., Williams, N., Gazdar, A. F., Posner, B. A., Brekken, R. A., Sood, A. K., Deberardinis, R. J., Roth, M. G., Minna, J. D. and White, M. A. (2013). Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155(3): 552-566.
  5. Villalta, S. A., Lang, J., Kubeck, S., Kabre, B., Szot, G. L., Calderon, B., Wasserfall, C., Atkinson, M. A., Brekken, R. A., Pullen, N., Arch, R. H. and Bluestone, J. A. (2013). Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes 62(8): 2870-2878.
  6. Wang, L., Chang, J., Varghese, D., Dellinger, M., Kumar, S., Best, A. M., Ruiz, J., Bruick, R., Pena-Llopis, S., Xu, J., Babinski, D. J., Frantz, D. E., Brekken, R. A., Quinn, A. M., Simeonov, A., Easmon, J. and Martinez, E. D. (2013). A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 4: 2035.
  7. Hooda, J., Cadinu, D., Alam, M. M., Shah, A., Cao, T. M., Sullivan, L. A., Brekken, R. and Zhang, L. (2013). Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS One 8(5): e63402.
  8. Currier, M. A., Eshun, F. K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W. F., Frischer, J. S., Collins, M. H., Leddon, J. L., Baird, W. H., Haseley, A., Streby, K. A., Wang, P. Y., Hendrickson, B. W., Brekken, R. A., Kaur, B., Hildeman, D. and Cripe, T. P. (2013). VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther 21(5): 1014-1023.
  9. Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, II, Heguy, A., Teruya-Feldstein, J. and Scaglioni, P. P. (2013). RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov 3(4): 444-457.
  10. Chatterjee, S., Heukamp, L. C., Siobal, M., Schottle, J., Wieczorek, C., Peifer, M., Frasca, D., Koker, M., Konig, K., Meder, L., Rauh, D., Buettner, R., Wolf, J., Brekken, R. A., Neumaier, B., Christofori, G., Thomas, R. K. and Ullrich, R. T. (2013). Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 123(4): 1732-1740.
  11. Said, N., Frierson, H. F., Sanchez-Carbayo, M., Brekken, R. A. and Theodorescu, D. (2013). Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 123(2): 751-766.
  12. Li, X., Zhou, Q., Hanus, J., Anderson, C., Zhang, H., Dellinger, M., Brekken, R. and Wang, S. (2013). Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model. Mol Pharm 10(1): 307-318.
  13. Gerber, D. E., Gupta, P., Dellinger, M. T., Toombs, J. E., Peyton, M., Duignan, I., Malaby, J., Bailey, T., Burns, C., Brekken, R. A. and Loizos, N. (2012). Stromal platelet-derived growth factor receptor alpha (PDGFRalpha) provides a therapeutic target independent of tumor cell PDGFRalpha expression in lung cancer xenografts. Mol Cancer Ther 11(11): 2473-2482.
  14. Hezel, A. F., Deshpande, V., Zimmerman, S. M., Contino, G., Alagesan, B., O'Dell, M. R., Rivera, L. B., Harper, J., Lonning, S., Brekken, R. A. and Bardeesy, N. (2012). TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res 72(18): 4840-4845.
  15. Asterholm, I. W., McDonald, J., Blanchard, P. G., Sinha, M., Xiao, Q., Mistry, J., Rutkowski, J. M., Deshaies, Y., Brekken, R. A. and Scherer, P. E. (2012). Lack of "immunological fitness" during fasting in metabolically challenged animals. J Lipid Res 53(7): 1254-1267.
  16. Sun, K., Wernstedt Asterholm, I., Kusminski, C. M., Bueno, A. C., Wang, Z. V., Pollard, J. W., Brekken, R. A. and Scherer, P. E. (2012). Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 109(15): 5874-5879.
  17. Benson, D. D., Beck, A. W., Burdine, M. S., Brekken, R., Silliman, C. C. and Barnett, C. C., Jr. (2012). Accumulation of pro-cancer cytokines in the plasma fraction of stored packed red cells. J Gastrointest Surg 16(3): 460-468.
  18. Greer, R. M., Peyton, M., Larsen, J. E., Girard, L., Xie, Y., Gazdar, A. F., Harran, P., Wang, L., Brekken, R. A., Wang, X. and Minna, J. D. (2011). SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-alpha-independent manner. Cancer Res 71(24): 7640-7648.
  19. Girotti, M. R., Fernandez, M., Lopez, J. A., Camafeita, E., Fernandez, E. A., Albar, J. P., Benedetti, L. G., Valacco, M. P., Brekken, R. A., Podhajcer, O. L. and Llera, A. S. (2011). SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha2beta1 integrin axis. J Invest Dermatol 131(12): 2438-2447.
  20. Zhang, Y. A., Maitra, A., Hsieh, J. T., Rudin, C. M., Peacock, C. D., Karikari, C., Brekken, R. A., Stastny, V., Gao, B., Girard, L., Wistuba, I., Frenkel, E., Minna, J. D. and Gazdar, A. F. (2011). Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther 12(7): 617-628.
  21. Harris, B. S., Zhang, Y., Card, L., Rivera, L. B., Brekken, R. A. and Bradshaw, A. D. (2011). SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol 301(3): H841-847.
  22. Sierko, E., Wojtukiewicz, M. Z., Zimnoch, L., Thorpe, P. E., Brekken, R. A. and Kisiel, W. (2011). Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. Anticancer Res 31(3): 843-847.
  23. Ou, Y. H., Torres, M., Ram, R., Formstecher, E., Roland, C., Cheng, T., Brekken, R., Wurz, R., Tasker, A., Polverino, T., Tan, S. L. and White, M. A. (2011). TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 41(4): 458-470.
  24. Awasthi, N., Kirane, A., Schwarz, M. A., Toombs, J. E., Brekken, R. A. and Schwarz, R. E. (2011). Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer 11: 15.
  25. Li, L. S., Bey, E. A., Dong, Y., Meng, J., Patra, B., Yan, J., Xie, X. J., Brekken, R. A., Barnett, C. C., Bornmann, W. G., Gao, J. and Boothman, D. A. (2011). Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res 17(2): 275-285.
  26. Ramos, A. L., Darabi, R., Akbarloo, N., Borges, L., Catanese, J., Dineen, S. P., Brekken, R. A. and Perlingeiro, R. C. (2010). Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. Circ Res 107(12): 1460-1469.
  27. De Leon-Rodriguez, L. M., Lubag, A., Udugamasooriya, D. G., Proneth, B., Brekken, R. A., Sun, X., Kodadek, T. and Dean Sherry, A. (2010). MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc 132(37): 12829-12831.
  28. Chambliss, K. L., Wu, Q., Oltmann, S., Konaniah, E. S., Umetani, M., Korach, K. S., Thomas, G. D., Mineo, C., Yuhanna, I. S., Kim, S. H., Madak-Erdogan, Z., Maggi, A., Dineen, S. P., Roland, C. L., Hui, D. Y., Brekken, R. A., Katzenellenbogen, J. A., Katzenellenbogen, B. S. and Shaul, P. W. (2010). Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120(7): 2319-2330.
  29. Villasenor, A., Wang, Z. V., Rivera, L. B., Ocal, O., Asterholm, I. W., Scherer, P. E., Brekken, R. A., Cleaver, O. and Wilkie, T. M. (2010). Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. Dis Model Mech 3(9-10): 567-580.
  30. Hohenstein, B., Colin, M., Foellmer, C., Amann, K. U., Brekken, R. A., Daniel, C. and Hugo, C. P. (2010). Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrol Dial Transplant 25(10): 3170-3180.
  31. Roland, C. L., Dineen, S. P., Toombs, J. E., Carbon, J. G., Smith, C. W., Brekken, R. A. and Barnett, C. C., Jr. (2010). Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood) 235(2): 263-270.
  32. Barnett, C. C., Jr., Beck, A. W., Holloway, S. E., Kehler, M., Schluterman, M. K., Brekken, R. A., Fleming, J. B. and Silliman, C. C. (2010). Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. Cancer 116(16): 3862-3874.
  33. Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C., Varella-Garcia, M., Vooder, T., Wistuba, II, Lam, S., Brekken, R., Toyooka, S., Minna, J. D., Lam, W. L. and Gazdar, A. F. (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4(10): e7464.
  34. Albuquerque, R. J., Hayashi, T., Cho, W. G., Kleinman, M. E., Dridi, S., Takeda, A., Baffi, J. Z., Yamada, K., Kaneko, H., Green, M. G., Chappell, J., Wilting, J., Weich, H. A., Yamagami, S., Amano, S., Mizuki, N., Alexander, J. S., Peterson, M. L., Brekken, R. A., Hirashima, M., Capoor, S., Usui, T., Ambati, B. K. and Ambati, J. (2009). Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 15(9): 1023-1030.
  35. Halberg, N., Khan, T., Trujillo, M. E., Wernstedt-Asterholm, I., Attie, A. D., Sherwani, S., Wang, Z. V., Landskroner-Eiger, S., Dineen, S., Magalang, U. J., Brekken, R. A. and Scherer, P. E. (2009). Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29(16): 4467-4483.
  36. Matsuo, Y., Campbell, P. M., Brekken, R. A., Sung, B., Ouellette, M. M., Fleming, J. B., Aggarwal, B. B., Der, C. J. and Guha, S. (2009). K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 7(6): 799-808.
  37. Arguello, A. A., Fischer, S. J., Schonborn, J. R., Markus, R. W., Brekken, R. A. and Eisch, A. J. (2009). Effect of chronic morphine on the dentate gyrus neurogenic microenvironment. Neuroscience 159(3): 1003-1010.

Invited reviews, commentaries and book chapters

  1. Brekken, R. A. (2014). Faulty ECM signaling facilitates autoimmune lymphomagenesis. Cancer Discov 4(1): 25-26.
  2. Huang, X, and Brekken, R. A. (2013). Revitalizing tumor immunity by targeting PS. Science & Technology.
  3. Ribeiro, N., Sousa, S. R., Brekken, R. A. and Monteiro, F. J. (2014). Role of SPARC in Bone Remodeling and Cancer‐Related Bone Metastasis. Journal of Cellular Biochemistry 115(1): 17-26.
  4. Wang, M., Brekken, R. A. (2013). FBLN5 (fibulin 5). Atlas Genet Cytogenet Oncol Haematol.
  5. Aguilera, K. Y. and Brekken, R. A. (2014). Recruitment and retention: factors that affect pericyte migration. Cell Mol Life Sci 71(2): 299-309.
  6. Brekken, R. A. (2013). A SPARC of originality. International Innovation (3): 17-19.
  7. Lynn, K. D. and Brekken, R. A. (2012). Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer? Cancer Discov 2(3): 211-213.
  8. Rivera, L. B., Bradshaw, A. D. and Brekken, R. A. (2011). The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 68(19): 3165-3173.
  9. Korpanty, G. and Brekken, R. A. (2011). An update on vascular targeting for cancer therapy. Therapy 8: 403-413.
  10. Schluterman, M. K. and Brekken, R. A. (2011). The function of fibulin-5 in the tumor microenvironment. In: Siemann, D. (ed). Vascular Disrupting Agents. John Wiley & Sons.
  11. Korpanty, G., Sullivan, L. A., Smyth, E., Carney, D. N. and Brekken, R. A. (2010). Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol 2010: 652320.
  12. Lynn, K. D., Roland, C. L. and Brekken, R. A. (2010). VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers (Basel) 2(2): 970-988.
  13. Sullivan, L. A. and Brekken, R. A. (2010). The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2(2): 165-175.
  14. Korpanty, G., Smyth, E., Sullivan, L. A., Brekken, R. A. and Carney, D. N. (2010). Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 235(1): 3-9.
  15. Yanagisawa, H., Schluterman, M. K. and Brekken, R. A. (2009). Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal 3(3-4): 337-347.
  16. Arnold, S. A. and Brekken, R. A. (2009). SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 3(3-4): 255-273.
  17. Korpanty, G. and Brekken, R. A. (2010). Targeting tumor vasculature with microbubbles. In: Meyer, T. (ed). Vascular Targeting Therapy for Cancer. Springer.
  18. Brekken, R. A. and Bradshaw, A. D. (2010). The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell: ECM Interaction. In: Zent, R. and Pozzi, A. (eds). Cell-Extracellular Matrix Interaction in Cancer. Springer.
Other Resources
For Advertisers
For Authors
About
©  Bio-protocol LLC. ISSN: 2331-8325 Terms of ServicePrivacy Policy
Find out more
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.